Literature DB >> 17036057

Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells.

H J Bontkes1, D Kramer, J J Ruizendaal, E W M Kueter, V F I van Tendeloo, C J L M Meijer, E Hooijberg.   

Abstract

Dendritic cells (DC) transfected with messenger RNA (mRNA) encoding tumor-associated antigens (TAA) are able to induce potent tumor-specific T-cell responses directed to a broad spectrum of tumor-associated epitopes. The in vitro generation of DC possessing all the features crucial for the induction of type 1 immune responses, such as mature state, migratory potential and interleukin-12 (IL-12p70) production is complicated. Particularly migratory potential is inversely correlated with IL-12p70 production after maturation with prostaglandin E2 (PGE2), which is included in maturation cocktails currently used in most vaccination trials. Here, we show that transfection of PGE2 matured DC with a single mRNA strain encoding for ubiquitin followed by a TAA which was linked to IL-12 by a self-cleaving 2A sequence, produced biological active IL-12p70 and were able to present the transfected TAA up to 72 h after transfection. Furthermore, use of the anti-reverse cap analog for in vitro transcription of the IL-12 mRNA enabled constitutive IL-12p70 production for up to 5 days. These transfected mature DC migrated efficiently towards lymph node derived chemokines. DCs constitutively expressing IL-12p70, generate TAA-specific cytotoxic T cells with an high functional avidity, independent of CD4+ T-cell help.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17036057     DOI: 10.1038/sj.gt.3302874

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  21 in total

Review 1.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 2.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

3.  Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.

Authors:  Sébastien Anguille; Evelien L J M Smits; Nathalie Cools; Herman Goossens; Zwi N Berneman; Vigor F I Van Tendeloo
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

Review 4.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

5.  Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses.

Authors:  Jaewoo Lee; Claudia M Dollins; David Boczkowski; Bruce A Sullenger; Smita Nair
Journal:  Immunology       Date:  2008-04-03       Impact factor: 7.397

6.  Dendritic cell mediated delivery of plasmid DNA encoding LAMP/HIV-1 Gag fusion immunogen enhances T cell epitope responses in HLA DR4 transgenic mice.

Authors:  Gregory G Simon; Yongli Hu; Asif M Khan; Jingshi Zhou; Jerome Salmon; Priya R Chikhlikar; Keun-Ok Jung; Ernesto T A Marques; J Thomas August
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

7.  Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells.

Authors:  Kira Minkis; Daniel G Kavanagh; Galit Alter; Dusan Bogunovic; David O'Neill; Sylvia Adams; Anna Pavlick; Bruce D Walker; Mark A Brockman; Rajesh T Gandhi; Nina Bhardwaj
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

8.  Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses.

Authors:  Ellen Van Gulck; Nathalie Cools; Derek Atkinson; Lotte Bracke; Katleen Vereecken; Marc Vekemans; Viggo F I Van Tendeloo; Zwi N Berneman; Guido Vanham
Journal:  Clin Dev Immunol       Date:  2012-07-12

9.  Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.

Authors:  Annelies W Turksma; Hetty J Bontkes; Janneke J Ruizendaal; Kirsten B J Scholten; Johanneke Akershoek; Shakila Rampersad; Laura M Moesbergen; Saskia A G M Cillessen; Saskia J A M Santegoets; Tanja D de Gruijl; C René Leemans; Chris J L M Meijer; Erik Hooijberg
Journal:  J Transl Med       Date:  2013-06-20       Impact factor: 5.531

Review 10.  Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.

Authors:  Ilse Van Brussel; Zwi N Berneman; Nathalie Cools
Journal:  Mediators Inflamm       Date:  2012-07-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.